


Assessing the added value of new technologies

Maria Kalogeropoulou, Sr Consultant HTA

HTA Conference-The role of HTA in the era of radical changes & disruptive innovation
Athens, 23 March 2021


Main objectives of HTA

Inform policy and decision-making in health care, especially on how best to allocate limited funds




Where does value come from?

Combine evidence and analysis to support and quantify value arguments




Typology of value-added medicines

Focusing on patient benefit and impact on society




The Importance of Attributes for HTA Frameworks

Greek HTA requirements compared with EUNETHTA criteria



Ranking of attributes by a sample of EU HTA experts

Low ranking of innovation



A scale from 1 to 6 (1 representing the lowest importance and 6 the highest)

Key questions for any decision-maker

Four criteria of HTA

Unmet medical
need

1. Agree there is an **unmet therapeutic need**

Therapeutic value
(clinical evidence)

2. Agree that the product offers **clinical value** (based on disease severity, burden of disease, safety, tolerability) and **added therapeutic value** (clinical evidence demonstrates that a product meets unmet medical need better than currently available alternatives)

Value for money
(cost-effectiveness)


3. Agree that the product offers good **value for money** (i.e. it is cost-effective)

Affordability
(budget impact)

4. Agree that the product is **affordable** (i.e. it has a favorable budget impact)


Economic Evaluation


Two key economic questions need to be answered



Data collection

Where do data come from?



 Input parameters drive conclusion!!!

Weaknesses of HTA process in Greece


Issues impacting on HTA's effective use for meeting key objectives



Establish a transparent and efficient HTA evaluation system and reimbursement processes


Right medicine to the right patient at the right time

Health Technology Assessment



Establish rigorous and robust procedures for efficient HTA

Improving submission timelines and expediting the evaluation process



Perspective

Adopt a broader perspective

HTA decision frameworks should adopt a broader perspective in order to better reflect patients' and society's views of healthcare

- In Europe, when cost-effectiveness is used by HTA bodies, there is a variety of perspectives that are considered:
 - Societal perspective (e.g., in Sweden)
 - National health insurance perspective (e.g., in the UK)
 - Mixed perspective (e.g., in France)
- Due to the potentially substantial impact of productivity costs on cost-effectiveness outcomes, they should be considered in HTA decision frameworks
- This may enhance the efficiency related to usage of medicines to improve overall society performance

Patient Centricity

Early contact with patient/ consumer organizations

HTA decision frameworks should be patient-centric and consider a patient perspective including patient-reported outcomes, patient-centered outcomes, and patient preferences

- Need to promote development of validated PROs instruments, compliant with HTA requirements
- Need to encourage research to identify and disseminate which outcomes are patient centric, so that HTA agencies may value them appropriately
- Patients' preferences, when adequately elicited, should be clearly considered in HTA decision frameworks





Thank you!